Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Correlation between clinical outcomes, CTC changes and AR-V7 in first-line abiraterone-treated mCRPC
DRKS00011614Phase 3Terminated
- Sponsor
- Medical Faculty Magdeburg
- Start
- Mar 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abiraterone, prednisone and prednisolone in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Medical Faculty Magdeburg. Started Mar 2017; status: terminated.
02
Drugs
abirateroneprednisoneprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on DRKS00011614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00011614.